Endocrine functions of adipose tissue: focus on adiponectin (Q37338559)

19 August 2017

1 reference

title

Endocrine functions of adipose tissue: focus on adiponectin (English)

1 reference

19 August 2017

James R Sowers

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

32-8; discussion 39-40

1 reference

Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Body mass, fitness and survival in veteran patients: another obesity paradox?

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Obesity as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Metabolic risk factors and renal disease

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Body-mass index and mortality in Korean men and women.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Abdominal adiposity and cardiometabolic risk: do we have all the answers?

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

The cardiometabolic syndrome and liver disease

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

ACRP30, a new hormone controlling fat and glucose metabolism

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Adipose tissue, inflammation, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Association of hypoadiponectinemia with coronary artery disease in men

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Plasma adiponectin levels and risk of myocardial infarction in men.

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Inflammation, insulin resistance, and adiposity: a study of first-degree relatives of type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Changes of adiponectin oligomer composition by moderate weight reduction

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016/S1098-3597(08)60026-5

7 January 2021

10.1016/S1098-3597(08)60026-5

Identifiers

DOI

1 reference

19 August 2017

1 reference